<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Abeona Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/abeona-therapeutics-inc</link>
<description>Latest news and press releases for Abeona Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/abeona-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683540d20eaa31f6af9677e7.webp</url>
<title>Abeona Therapeutics Inc</title>
<link>https://6ix.com/company/abeona-therapeutics-inc</link>
</image>
<item>
<title>Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-appointment-of-keith-a-goldan-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-appointment-of-keith-a-goldan-to-its-board-of-directors</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent</description>
</item>
<item>
<title>Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-new-qualified-treatment-center-for-zevaskynr-in-new-york-58</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-new-qualified-treatment-center-for-zevaskynr-in-new-york-58</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University</description>
</item>
<item>
<title>Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-reports-full-year-2025-financial-results-and-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-reports-full-year-2025-financial-results-and-corporate-updates</guid>
<pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
<description>- First ZEVASKYN® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2025 and recent operational progress. “2026 is about building a steady cadence of biopsies and treatments,” said Vish Seshadri, Chief Execut</description>
</item>
<item>
<title>Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-provides-business-update-highlighting-building-momentum-in-zevaskynr-commercial-launch</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-provides-business-update-highlighting-building-momentum-in-zevaskynr-commercial-launch</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s</description>
</item>
<item>
<title>Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-date-of-fourth-quarter-full-year-2025-financial-results-and-participation-in-upcoming-2026-leerink-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-date-of-fourth-quarter-full-year-2025-financial-results-and-participation-in-upcoming-2026-leerink-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 12:30:00 GMT</pubDate>
<description>CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-on</description>
</item>
<item>
<title>Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-new-employee-inducement-grants-under-nasdaq-listing</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-new-employee-inducement-grants-under-nasdaq-listing</guid>
<pubDate>Wed, 31 Dec 2025 05:00:00 GMT</pubDate>
<description>CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive</description>
</item>
<item>
<title>Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-appointment-mohamad-tabrizi-chief-business-officer</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-appointment-mohamad-tabrizi-chief-business-officer</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as</description>
</item>
<item>
<title>Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-new-qualified-treatment-center-zevaskynr-texas-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-new-qualified-treatment-center-zevaskynr-texas-2025-12</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch</description>
</item>
<item>
<title>Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-first-patient-treatment-zevaskynr-gene-therapy-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-first-patient-treatment-zevaskynr-gene-therapy-2025-12</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved</description>
</item>
<item>
<title>Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-reports-third-quarter-2025-financial-results-and-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-reports-third-quarter-2025-financial-results-and-corporate</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>- First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand</description>
</item>
<item>
<title>Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-date-third-quarter-financial-results-and-upcoming</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-date-third-quarter-financial-results-and-upcoming</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12,</description>
</item>
<item>
<title>Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-permanent-j-code-zevaskynr-prademagene-zamikeracel</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-permanent-j-code-zevaskynr-prademagene-zamikeracel</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene</description>
</item>
<item>
<title>Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-appoints-james-gow-md-mba-ms-mhcm-senior-vice-president-head</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-appoints-james-gow-md-mba-ms-mhcm-senior-vice-president-head</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene</description>
</item>
<item>
<title>Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-abo-503-gene-therapy-x-linked-retinoschisis-xlrs</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-abo-503-gene-therapy-x-linked-retinoschisis-xlrs</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapies CLEVELAND, Oct. 13,</description>
</item>
<item>
<title>Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-and-childrens-hospital-colorado-announce-newest-treatment-center</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-and-childrens-hospital-colorado-announce-newest-treatment-center</guid>
<pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
<description>CLEVELAND, Ohio and AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) and Children's Hospital Colorado today announced</description>
</item>
<item>
<title>Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-participation-upcoming-investor-conferences-2025-08-29</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-announces-participation-upcoming-investor-conferences-2025-08-29</guid>
<pubDate>Fri, 29 Aug 2025 04:00:00 GMT</pubDate>
<description>CLEVELAND, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in</description>
</item>
<item>
<title>Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-reports-second-quarter-2025-financial-results-and-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/abeona-therapeuticsr-reports-second-quarter-2025-financial-results-and-corporate</guid>
<pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
<description>- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult</description>
</item>
<item>
<title>AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/ascellahealth-hub-partnership-with-abeona-therapeuticsr-supports-launch-success-of-novel-cell-based-gene-therapy-and-access-to-treatment-for-rare-disease-patients</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/ascellahealth-hub-partnership-with-abeona-therapeuticsr-supports-launch-success-of-novel-cell-based-gene-therapy-and-access-to-treatment-for-rare-disease-patients</guid>
<pubDate>Tue, 29 Jul 2025 14:00:00 GMT</pubDate>
<description>BERWYN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partnership with Abeona Therapeutics Inc. (Nasdaq: ABEO) in the successful pre-and-post launch commercialization of ZEVASKYN™, an FDA-approved cell-based gene therapy. Working as a collaborative partner, AscellaHealth designed and executed patient-centric, end-to-end solutions to address unique clinical,</description>
</item>
<item>
<title>ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/zevaskyntm-gene-therapy-now-available-new-qualified-treatment-center-san-francisco</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/zevaskyntm-gene-therapy-now-available-new-qualified-treatment-center-san-francisco</guid>
<pubDate>Tue, 15 Jul 2025 04:00:00 GMT</pubDate>
<description>- Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics® and Stanford Medicine conducted</description>
</item>
<item>
<title>Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy</title>
<link>https://6ix.com/company/abeona-therapeutics-inc/news/bio-technes-simple-westerntm-technology-utilized-in-recent-fda-approval-of-zevaskyntm-cell-based-gene-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/abeona-therapeutics-inc/news/bio-technes-simple-westerntm-technology-utilized-in-recent-fda-approval-of-zevaskyntm-cell-based-gene-therapy</guid>
<pubDate>Mon, 14 Jul 2025 04:00:00 GMT</pubDate>
<description>MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in</description>
</item>
</channel>
</rss>